公开(公告)号：EP2498731B1

公开(公告)日：2020-01-22

申请号：EP10830654.9

申请日：2010-11-10

申请人： Chiesi Farmaceutici S.p.A.

发明人： ARCULUS-MEANWELL, Clive Arthur ,  SKERJANEC, Simona

IPC分类号： A61F2/82 ,  A61L27/54 ,  A61L33/04 ,  A61P7/02 ,  A61K31/7076 ,  A61K38/58 ,  A61K9/00 ,  A61K9/19

公开(公告)号：EP3978002A1

公开(公告)日：2022-04-06

申请号：EP21205348.2

申请日：2013-05-29

申请人： Chiesi Farmaceutici S.p.A.

发明人： ARCULUS-MEANWELL Clive Arthur ,  SKERJANEC, Simona ,  PRATS, Jayne ,  SCHNEIDER, David J.

IPC分类号： A61K31/7064 ,  A61P9/00

摘要： Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y 12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.

公开(公告)号：EP3345481A1

公开(公告)日：2018-07-11

申请号：EP18156791.8

申请日：2012-08-10

申请人： Chiesi Farmaceutici S.p.a.

发明人： CHEN, Lisa Ruderman ,  SKERJANEC, Simona ,  PRATS, Jayne ,  TODD, Meredith ,  BELL, Dawn

IPC分类号： A01N43/04 ,  A61K31/7076 ,  A61K31/4365 ,  A61P7/02

CPC分类号： A61K31/7076 ,  A61K31/00 ,  A61K31/4365 ,  A61K2300/00

摘要： There is provided a reversible short-acting P2Y 12 inhibitor for use in a method of maintaining or reducing platelet activity in a subject undergoing an invasive procedure, wherein the reversible short-acting P2Y 12 inhibitor is cangrelor, wherein the administration of cangrelor is sufficient to reduce or maintain at least 60% platelet inhibition or PRU values less than 240 prior to the patient undergoing an invasive procedure.